|
US5565215A
(en)
|
1993-07-23 |
1996-10-15 |
Massachusettes Institute Of Technology |
Biodegradable injectable particles for imaging
|
|
GB9322014D0
(en)
|
1993-10-26 |
1993-12-15 |
Co Ordinated Drug Dev |
Improvements in and relating to carrier particles for use in dry powder inhalers
|
|
SE9401109D0
(sv)
|
1994-03-31 |
1994-03-31 |
Leiras Oy |
Opthalmic composition II
|
|
SE9401108D0
(sv)
|
1994-03-31 |
1994-03-31 |
Leiras Oy |
Ophthalmic composition I
|
|
GB9412273D0
(en)
|
1994-06-18 |
1994-08-10 |
Univ Nottingham |
Administration means
|
|
US6007845A
(en)
|
1994-07-22 |
1999-12-28 |
Massachusetts Institute Of Technology |
Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
|
|
GB9501841D0
(en)
|
1995-01-31 |
1995-03-22 |
Co Ordinated Drug Dev |
Improvements in and relating to carrier particles for use in dry powder inhalers
|
|
US6413539B1
(en)
|
1996-10-31 |
2002-07-02 |
Poly-Med, Inc. |
Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
|
|
GB9515182D0
(en)
|
1995-07-24 |
1995-09-20 |
Co Ordinated Drug Dev |
Improvements in and relating to powders for use in dry powder inhalers
|
|
US5635517B1
(en)
*
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
DE69717160T2
(de)
|
1996-09-13 |
2003-05-08 |
Mitsubishi Pharma Corp., Osaka |
Thienotriazolodiazepinverbindungen und ihre medizinischen anwendungen
|
|
EP1064277B1
(en)
|
1998-03-16 |
2005-06-15 |
Celgene Corporation |
2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
|
|
US6045501A
(en)
|
1998-08-28 |
2000-04-04 |
Celgene Corporation |
Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
|
|
GB9827145D0
(en)
|
1998-12-09 |
1999-02-03 |
Co Ordinated Drug Dev |
Improvements in or relating to powders
|
|
US6306663B1
(en)
|
1999-02-12 |
2001-10-23 |
Proteinex, Inc. |
Controlling protein levels in eucaryotic organisms
|
|
US6287588B1
(en)
|
1999-04-29 |
2001-09-11 |
Macromed, Inc. |
Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
|
|
EP1279406A4
(en)
|
2000-04-03 |
2007-10-24 |
Santen Pharmaceutical Co Ltd |
TRANSPORTERS AND DRUG DISPENSING SYSTEMS USING THESE
|
|
GB0009468D0
(en)
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formulations for use in inhaler devices
|
|
GB0009469D0
(en)
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formalities for use in inhaler devices
|
|
US6589549B2
(en)
|
2000-04-27 |
2003-07-08 |
Macromed, Incorporated |
Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
|
|
US6495164B1
(en)
|
2000-05-25 |
2002-12-17 |
Alkermes Controlled Therapeutics, Inc. I |
Preparation of injectable suspensions having improved injectability
|
|
PT1296651E
(pt)
|
2000-06-27 |
2008-02-12 |
Vectura Ltd |
Método para fazer partículas para serem usadas numa composição farmacêutica
|
|
GB2364919A
(en)
|
2000-07-21 |
2002-02-13 |
Cambridge Consultants |
Inhalers
|
|
US7041298B2
(en)
|
2000-09-08 |
2006-05-09 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
US7208157B2
(en)
|
2000-09-08 |
2007-04-24 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
US6315720B1
(en)
|
2000-10-23 |
2001-11-13 |
Celgene Corporation |
Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
|
|
ES2382636T3
(es)
|
2000-10-31 |
2012-06-12 |
Surmodics Pharmaceuticals, Inc. |
Método para producir composiciones para la administración mejorada de moléculas bioactivas
|
|
EP2168571B1
(en)
|
2000-11-30 |
2018-08-22 |
Vectura Limited |
Particles for use in a Pharmaceutical Composition
|
|
US20030045552A1
(en)
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
|
GB0122318D0
(en)
|
2001-09-14 |
2001-11-07 |
Novartis Ag |
Organic compounds
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
AU2003250190A1
(en)
|
2002-07-30 |
2004-02-23 |
Novartis Ag |
Combination of an aromatase inhibitor with a bisphosphonate
|
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
US7230012B2
(en)
|
2002-11-14 |
2007-06-12 |
Celgene Corporation |
Pharmaceutical compositions and dosage forms of thalidomide
|
|
US20050009910A1
(en)
|
2003-07-10 |
2005-01-13 |
Allergan, Inc. |
Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
|
|
NZ545484A
(en)
|
2003-09-15 |
2009-09-25 |
Vectura Ltd |
Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
|
|
CA2539324A1
(en)
|
2003-09-18 |
2005-03-31 |
Macusight, Inc. |
Transscleral delivery
|
|
GB0407627D0
(en)
|
2004-04-02 |
2004-05-05 |
Vectura Ltd |
Corkscrew pump
|
|
ES2246694B1
(es)
|
2004-04-29 |
2007-05-01 |
Instituto Cientifico Y Tecnologico De Navarra, S.A. |
Nanoparticulas pegiladas.
|
|
US8512738B2
(en)
|
2004-04-30 |
2013-08-20 |
Allergan, Inc. |
Biodegradable intravitreal tyrosine kinase implants
|
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
|
US20050244469A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Extended therapeutic effect ocular implant treatments
|
|
JP4974903B2
(ja)
|
2005-02-09 |
2012-07-11 |
参天製薬株式会社 |
疾患または状態を処置するための液体処方物
|
|
US8663639B2
(en)
|
2005-02-09 |
2014-03-04 |
Santen Pharmaceutical Co., Ltd. |
Formulations for treating ocular diseases and conditions
|
|
CN101495116A
(zh)
|
2005-03-22 |
2009-07-29 |
哈佛大学校长及研究员协会 |
蛋白降解病症的治疗
|
|
MX2007016039A
(es)
|
2005-06-17 |
2008-10-27 |
Univ North Carolina |
Metodos, sistemas y materiales de fabricacion de nanoparticulas.
|
|
US20070071756A1
(en)
|
2005-09-26 |
2007-03-29 |
Peyman Gholam A |
Delivery of an agent to ameliorate inflammation
|
|
WO2007056561A2
(en)
|
2005-11-09 |
2007-05-18 |
Liquidia Technologies, Inc. |
Medical device, materials, and methods
|
|
WO2007081876A2
(en)
|
2006-01-04 |
2007-07-19 |
Liquidia Technologies, Inc. |
Nanostructured surfaces for biomedical/biomaterial applications and processes thereof
|
|
US8663674B2
(en)
|
2006-01-13 |
2014-03-04 |
Surmodics, Inc. |
Microparticle containing matrices for drug delivery
|
|
PL2001466T3
(pl)
|
2006-03-23 |
2016-06-30 |
Santen Pharmaceutical Co Ltd |
Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
|
|
US20080166411A1
(en)
|
2006-04-10 |
2008-07-10 |
Pfizer Inc |
Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles
|
|
WO2007133808A2
(en)
|
2006-05-15 |
2007-11-22 |
Liquidia Technologies, Inc. |
Nano-particles for cosmetic applications
|
|
CL2007002218A1
(es)
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
MX2009001989A
(es)
|
2006-08-30 |
2009-03-09 |
Celgene Corp |
Compuestos de isoindolina 5-substituidos.
|
|
PL2076260T3
(pl)
|
2006-09-15 |
2011-08-31 |
Celgene Corp |
Związki N-metyloaminometylo-izoindolu, kompozycje zawierające te związki, oraz metody ich stosowania
|
|
DK2428513T3
(en)
|
2006-09-26 |
2017-08-21 |
Celgene Corp |
5-substituted quinazolinone derivatives as anti-cancer agents
|
|
WO2008100304A2
(en)
|
2006-11-15 |
2008-08-21 |
The University Of North Carolina At Chapel Hill |
Polymer particle composite having high fidelity order, size, and shape particles
|
|
KR101791757B1
(ko)
|
2007-03-20 |
2017-10-30 |
셀진 코포레이션 |
4'-ｏ-치환된 아이소인돌린 유도체 및 이를 포함하는 조성물 및 이의 사용 방법
|
|
WO2008122038A1
(en)
|
2007-04-02 |
2008-10-09 |
President And Fellows Of Harvard College |
Regulating autophagy
|
|
AU2008305581C1
(en)
|
2007-09-26 |
2014-12-11 |
Celgene Corporation |
6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
|
|
WO2009084693A1
(ja)
|
2007-12-28 |
2009-07-09 |
Mitsubishi Tanabe Pharma Corporation |
抗癌剤
|
|
WO2009100176A2
(en)
|
2008-02-07 |
2009-08-13 |
Abbott Laboratories |
Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
|
|
WO2009145842A2
(en)
|
2008-04-04 |
2009-12-03 |
Forsight Labs, Llc |
Therapeutic device for pain management and vision
|
|
CN102112118A
(zh)
|
2008-04-25 |
2011-06-29 |
北卡罗来纳-查佩尔山大学 |
特别用于非湿润模型的颗粒复制的可降解化合物及其使用方法
|
|
WO2009132206A1
(en)
|
2008-04-25 |
2009-10-29 |
Liquidia Technologies, Inc. |
Compositions and methods for intracellular delivery and release of cargo
|
|
US20090298882A1
(en)
|
2008-05-13 |
2009-12-03 |
Muller George W |
Thioxoisoindoline compounds and compositions comprising and methods of using the same
|
|
WO2010009087A1
(en)
|
2008-07-15 |
2010-01-21 |
Eyegate Pharmaceuticals, Inc. |
Iontophoretic delivery of a controlled-release formulation in the eye
|
|
PE20110547A1
(es)
|
2008-10-29 |
2011-08-04 |
Celgene Corp |
Compuestos de isoindolina con actividad anticancerigena
|
|
US8444907B2
(en)
|
2008-12-05 |
2013-05-21 |
Liquidia Technologies, Inc. |
Method for producing patterned materials
|
|
US8399006B2
(en)
|
2009-01-29 |
2013-03-19 |
Forsight Vision4, Inc. |
Posterior segment drug delivery
|
|
US8623395B2
(en)
|
2010-01-29 |
2014-01-07 |
Forsight Vision4, Inc. |
Implantable therapeutic device
|
|
US20120052041A1
(en)
|
2009-02-04 |
2012-03-01 |
The Brigham And Women's Hospital, Inc. |
Polymeric nanoparticles with enhanced drug-loading and methods of use thereof
|
|
EP2395930A4
(en)
|
2009-02-10 |
2013-04-10 |
Psivida Inc |
EYE TROWART ASSEMBLY
|
|
PL2401027T3
(pl)
|
2009-02-26 |
2018-04-30 |
The University Of North Carolina At Chapel Hill |
Układ do interwencyjnego dostarczania leku
|
|
US20120135089A1
(en)
|
2009-03-17 |
2012-05-31 |
Stockwell Brent R |
E3 ligase inhibitors
|
|
US10952965B2
(en)
|
2009-05-15 |
2021-03-23 |
Baxter International Inc. |
Compositions and methods for drug delivery
|
|
AU2010249615B2
(en)
|
2009-05-19 |
2013-07-18 |
Celgene Corporation |
Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
|
|
EP2437684B1
(en)
|
2009-06-03 |
2022-06-15 |
ForSight Vision5, Inc. |
Anterior segment drug delivery
|
|
US20120114554A1
(en)
|
2009-07-13 |
2012-05-10 |
Liquidia Technologies, Inc. |
Engineered Aerosol Particles, And Associated Methods
|
|
NZ620174A
(en)
|
2009-09-16 |
2016-08-26 |
Celgene Avilomics Res Inc |
Protein kinase conjugates and inhibitors
|
|
US9498385B2
(en)
|
2009-10-23 |
2016-11-22 |
Nexisvision, Inc. |
Conformable therapeutic shield for vision and pain
|
|
WO2011050327A1
(en)
|
2009-10-23 |
2011-04-28 |
Forsight Labs Llc |
Corneal denervation for treatment of ocular pain
|
|
MX336731B
(es)
|
2010-01-28 |
2016-01-28 |
Harvard College |
Composiciones y metodos para potenciar la actividad de proteasoma.
|
|
US10166142B2
(en)
|
2010-01-29 |
2019-01-01 |
Forsight Vision4, Inc. |
Small molecule delivery with implantable therapeutic device
|
|
WO2011097218A1
(en)
|
2010-02-02 |
2011-08-11 |
Wayne State University |
Anti-cancer therapeutic agents
|
|
US20130071349A1
(en)
|
2010-03-02 |
2013-03-21 |
Allergan, Inc. |
Biodegradable polymers for lowering intraocular pressure
|
|
PL2902030T3
(pl)
|
2010-05-14 |
2017-07-31 |
Dana-Farber Cancer Institute, Inc. |
Związki tienotriazolodiazepinowe do leczenia nowotworu
|
|
HUE033581T2
(hu)
|
2010-06-10 |
2017-12-28 |
Seragon Pharmaceuticals Inc |
Ösztrogén receptor modulátorok és alkalmazásaik
|
|
SG186389A1
(en)
|
2010-06-30 |
2013-01-30 |
Univ Brandeis |
Small-molecule-targeted protein degradation
|
|
SI2600812T1
(sl)
|
2010-08-05 |
2021-12-31 |
ForSight Vision4, Inc., |
Naprava za zdravljenje očesa
|
|
JP6111194B2
(ja)
|
2010-08-05 |
2017-04-05 |
フォーサイト・ビジョン フォー・インコーポレーテッド |
組み合わせ薬物送達方法および装置
|
|
EP3861969A1
(en)
|
2010-08-05 |
2021-08-11 |
ForSight Vision4, Inc. |
Injector apparatus for drug delivery
|
|
US20130274692A1
(en)
|
2010-08-05 |
2013-10-17 |
Yair Alster |
Subconjuctival implant for posterior segment drug delivery
|
|
GB2483736B
(en)
|
2010-09-16 |
2012-08-29 |
Aragon Pharmaceuticals Inc |
Estrogen receptor modulators and uses thereof
|
|
WO2012065006A2
(en)
|
2010-11-11 |
2012-05-18 |
Forsight Vision4, Inc. |
Methods and apparatus to determine porous structures for drug delivery
|
|
TW201304822A
(zh)
|
2010-11-15 |
2013-02-01 |
Vectura Ltd |
組成物及用途
|
|
WO2012068549A2
(en)
|
2010-11-19 |
2012-05-24 |
Forsight Vision4, Inc. |
Therapeutic agent formulations for implanted devices
|
|
US9249161B2
(en)
|
2010-12-02 |
2016-02-02 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
|
AU2011338615B2
(en)
|
2010-12-07 |
2017-07-27 |
Yale University |
Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
|
|
WO2012079022A1
(en)
|
2010-12-10 |
2012-06-14 |
Concert Pharmaceuticals, Inc. |
Substituted dioxopiperidinyl phthalimide derivatives
|
|
BRPI1100318A2
(pt)
|
2011-02-18 |
2013-05-21 |
Univ Estadual Paulista Jelio De Mesquita Filho |
processo de obtenÇço de compostos derivados derivados de anti-inflamatàrios esteràides (aies), composiÇÕes farmacÊuticas contendo tais compostos e seus usos no tratamento de doenÇas de carÁter inflamatàrio.
|
|
EP2723338A2
(en)
|
2011-06-24 |
2014-04-30 |
The Trustees of Stevens Institute of Technology |
Selective inhibitors of histone deacetylase isoform 6 and methods thereof
|
|
EP2755615B1
(en)
|
2011-09-14 |
2022-04-06 |
Forsight Vision5, Inc. |
Ocular insert apparatus
|
|
RS61758B1
(sr)
|
2011-09-16 |
2021-05-31 |
Forsight Vision4 Inc |
Aparati za razmenu tečnosti
|
|
CA2850987C
(en)
|
2011-10-17 |
2019-10-15 |
Biotheryx, Inc. |
Substituted biaryl alkyl amides
|
|
US20150037428A1
(en)
|
2011-11-29 |
2015-02-05 |
The University Of North Carolina At Chapel Hill |
Geometrically engineered particles and methods for modulating macrophage or immune responses
|
|
PT2797652T
(pt)
|
2011-12-27 |
2019-02-19 |
Vectura Gmbh |
Dispositivo para inalação com sistema de feedback
|
|
CA2861066C
(en)
|
2012-01-12 |
2024-01-02 |
Yale University |
Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
|
|
WO2013106646A2
(en)
|
2012-01-12 |
2013-07-18 |
Yale University |
Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
|
|
US10010448B2
(en)
|
2012-02-03 |
2018-07-03 |
Forsight Vision4, Inc. |
Insertion and removal methods and apparatus for therapeutic devices
|
|
CN104271187B
(zh)
|
2012-03-09 |
2018-01-12 |
维克多瑞有限责任公司 |
吸入装置的混合通道与吸入装置
|
|
US20140107025A1
(en)
|
2012-04-16 |
2014-04-17 |
Jade Therapeutics, Llc |
Ocular drug delivery system
|
|
US20150119435A1
(en)
|
2012-05-11 |
2015-04-30 |
Yale University |
Compounds useful for promoting protein degradation and methods using same
|
|
BR112015005878A2
(pt)
|
2012-09-17 |
2017-07-04 |
Bind Therapeutics Inc |
nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas
|
|
JP2015532928A
(ja)
|
2012-09-20 |
2015-11-16 |
アキナ， インク．Ａｋｉｎａ， Ｉｎｃ． |
充填材料を含有する生体分解可能なマイクロカプセル
|
|
US9758522B2
(en)
|
2012-10-19 |
2017-09-12 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
|
DK2911623T3
(da)
|
2012-10-26 |
2019-10-28 |
Forsight Vision5 Inc |
Oftalmisk system til langvarig frigivelse af lægemiddel til øjet
|
|
PL2724741T3
(pl)
|
2012-10-26 |
2017-11-30 |
Vectura Gmbh |
Urządzenie inhalacyjne do stosowania w terapii aerozolowej
|
|
EP2914296B2
(en)
|
2012-11-01 |
2021-09-29 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using pi3 kinase isoform modulators
|
|
CN105073768A
(zh)
|
2013-03-13 |
2015-11-18 |
达纳-法伯癌症研究所股份有限公司 |
Ras抑制剂及其用途
|
|
WO2014140077A1
(en)
|
2013-03-14 |
2014-09-18 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Furopyridines as bromodomain inhibitors
|
|
CA2905496A1
(en)
|
2013-03-14 |
2014-09-25 |
Forsight Vision4, Inc. |
Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
|
|
US9790188B2
(en)
|
2013-03-15 |
2017-10-17 |
Whitehead Institute For Biomedical Research |
Benzimidazole derivatives and uses thereof
|
|
ES2972168T3
(es)
|
2013-03-28 |
2024-06-11 |
Forsight Vision4 Inc |
Implante oftálmico para administración de sustancias terapéuticas
|
|
ES2834964T3
(es)
|
2013-04-01 |
2021-06-21 |
Allergan Inc |
Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida
|
|
CN103421061A
(zh)
|
2013-08-14 |
2013-12-04 |
中国药科大学 |
来那度胺衍生物、其制法及其医药用途
|
|
CA2927321A1
(en)
|
2013-10-15 |
2015-04-23 |
Forsight Vision5, Inc. |
Formulations and methods for increasing or reducing mucus
|
|
WO2015085234A1
(en)
|
2013-12-06 |
2015-06-11 |
Forsight Vision4, Inc. |
Implantable therapeutic devices
|
|
IL278381B2
(en)
|
2013-12-06 |
2024-08-01 |
Celgene Corp |
Methods for determining the effectiveness of a drug for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancer
|
|
MX2016007345A
(es)
|
2013-12-06 |
2016-12-09 |
Envisia Therapeutics Inc |
Implante intracameral para el tratamiento de una condicion ocular.
|
|
US20160058872A1
(en)
|
2014-04-14 |
2016-03-03 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
AU2015247817C1
(en)
|
2014-04-14 |
2022-02-10 |
Arvinas Operations, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
US20160022642A1
(en)
|
2014-07-25 |
2016-01-28 |
Yale University |
Compounds Useful for Promoting Protein Degradation and Methods Using Same
|
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
WO2016065139A1
(en)
|
2014-10-24 |
2016-04-28 |
Fl Therapeutics Llc |
3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin
|
|
JP6815318B2
(ja)
*
|
2014-12-23 |
2021-01-20 |
ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド |
二官能性分子によって標的化タンパク質分解を誘導する方法
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
GB201504314D0
(en)
|
2015-03-13 |
2015-04-29 |
Univ Dundee |
Small molecules
|
|
US10730870B2
(en)
|
2015-03-18 |
2020-08-04 |
Arvinas Operations, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
AU2016266942B2
(en)
|
2015-05-22 |
2018-10-18 |
Biotheryx, Inc. |
Compounds targeting proteins, compositions, methods, and uses thereof
|
|
HUE054149T2
(hu)
|
2015-06-04 |
2021-08-30 |
Arvinas Operations Inc |
Proteolízis imid-alapú modulátorai és ezekkel kapcsolatos felhasználási eljárások
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
WO2017011371A1
(en)
|
2015-07-10 |
2017-01-19 |
Arvinas, Inc |
Mdm2-based modulators of proteolysis and associated methods of use
|
|
CA2988436A1
(en)
|
2015-07-13 |
2017-01-19 |
Arvinas, Inc. |
Alanine-based modulators of proteolysis and associated methods of use
|
|
WO2017024318A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
WO2017024317A2
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
AU2016349781A1
(en)
|
2015-11-02 |
2018-05-10 |
Yale University |
Proteolysis targeting chimera compounds and methods of preparing and using same
|
|
US11395820B2
(en)
|
2016-03-16 |
2022-07-26 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Small molecules against cereblon to enhance effector t cell function
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
WO2017176958A1
(en)
|
2016-04-06 |
2017-10-12 |
The Regents Of The University Of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
|
AU2017246452C1
(en)
|
2016-04-06 |
2021-06-03 |
The Regents Of The University Of Michigan |
MDM2 protein degraders
|
|
MX384905B
(es)
|
2016-04-12 |
2025-03-14 |
Univ Michigan Regents |
Degradadores de proteínas de bromodominio y dominioextraterminal (bet).
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
EP3454862B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
WO2017197056A1
(en)
*
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Bromodomain targeting degronimers for target protein degradation
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
EP4491236A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
AU2017263574B2
(en)
|
2016-05-12 |
2022-11-17 |
The Regents Of The University Of Michigan |
ASH1L inhibitors and methods of treatment therewith
|
|
WO2017201069A1
(en)
|
2016-05-18 |
2017-11-23 |
Biotheryx, Inc. |
Oxoindoline derivatives as protein function modulators
|
|
EP3458101B1
(en)
|
2016-05-20 |
2020-12-30 |
H. Hoffnabb-La Roche Ag |
Protac antibody conjugates and methods of use
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
WO2018023029A1
(en)
|
2016-07-28 |
2018-02-01 |
Mayo Foundation For Medical Education And Research |
Small molecule activators of parkin enzyme function
|
|
EP3512855B1
(en)
|
2016-09-13 |
2022-07-27 |
The Regents of the University of Michigan |
Fused 1,4-oxazepines as bet protein degraders
|
|
CA3036841A1
(en)
|
2016-09-13 |
2018-03-22 |
The Regents Of The University Of Michigan |
Fused 1,4-diazepines as bet protein degraders
|
|
GB2554071A
(en)
|
2016-09-14 |
2018-03-28 |
Univ Dundee |
Small molecules
|
|
WO2018053354A1
(en)
|
2016-09-15 |
2018-03-22 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
WO2018071606A1
(en)
|
2016-10-11 |
2018-04-19 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
EP3535254A4
(en)
|
2016-11-01 |
2020-06-24 |
Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") |
COMPOUNDS FOR THE DEGRADATION OF MALT1
|
|
IL290809B2
(en)
|
2016-11-01 |
2024-01-01 |
Arvinas Operations Inc |
Tau-protein targeting protacs and associated methods of use
|
|
KR102674902B1
(ko)
|
2016-12-01 |
2024-06-14 |
아비나스 오퍼레이션스, 인코포레이티드 |
에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
|
|
CA3043938A1
(en)
|
2016-12-21 |
2018-06-28 |
Biotheryx, Inc. |
Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof
|
|
MX2019007646A
(es)
|
2016-12-23 |
2019-09-06 |
Arvinas Operations Inc |
Moleculas quimericas dirigidas a la proteolisis del egfr y metodos asociados de uso.
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
CN117510491A
(zh)
|
2016-12-23 |
2024-02-06 |
阿尔维纳斯运营股份有限公司 |
用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
AU2018211975B2
(en)
|
2017-01-26 |
2022-05-26 |
Arvinas Operations, Inc. |
Modulators of estrogen receptor proteolysis and associated methods of use
|
|
BR112019015484A2
(pt)
|
2017-01-31 |
2020-04-28 |
Arvinas Operations Inc |
ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
|
|
US10406165B2
(en)
|
2017-03-14 |
2019-09-10 |
Biotheryx, Inc. |
Compounds targeting proteins, compositions, methods, and uses thereof
|
|
EP3601245A1
(en)
|
2017-03-28 |
2020-02-05 |
The Regents of The University of Michigan |
Small molecule dcn1 inhibitors and therapeutic methods using the same
|
|
CN110740996B
(zh)
|
2017-04-10 |
2024-01-09 |
密执安大学评议会 |
共价小分子dcn1抑制剂和使用其的治疗方法
|
|
EP3609889B1
(en)
|
2017-04-14 |
2023-07-05 |
University Of Dundee |
Small molecules
|
|
TWI791552B
(zh)
|
2017-07-10 |
2023-02-11 |
美商西建公司 |
抗增生化合物及其使用方法
|
|
MX2020003190A
(es)
|
2017-09-22 |
2020-11-11 |
Kymera Therapeutics Inc |
Degradadores de proteinas y usos de los mismos.
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
JP2021512167A
(ja)
|
2018-01-30 |
2021-05-13 |
フォグホーン セラピューティクス インコーポレイテッドＦｏｇｈｏｒｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． |
障害を治療するための方法及び化合物
|
|
US11802132B2
(en)
|
2018-02-23 |
2023-10-31 |
Dana-Farber Cancer Institute, Inc. |
Small molecules for inducing selective protein degradation and uses thereof
|
|
CA3095912A1
(en)
|
2018-04-13 |
2019-10-17 |
Arvinas Operations, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
WO2019213005A1
(en)
|
2018-04-30 |
2019-11-07 |
Dana-Farber Cancer Institute, Inc. |
Small molecule degraders of polybromo-1 (pbrm1)
|
|
EP3813834B1
(en)
|
2018-06-29 |
2025-03-26 |
Dana-Farber Cancer Institute, Inc. |
New crbn modulators
|
|
KR20250020690A
(ko)
|
2018-06-29 |
2025-02-11 |
다나-파버 캔서 인스티튜트 인크. |
세레블론(crbn)에 대한 리간드
|
|
US12060366B2
(en)
|
2018-06-29 |
2024-08-13 |
Dana-Farber Cancer Institute, Inc. |
Bispecific degraders
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US20200038513A1
(en)
|
2018-07-26 |
2020-02-06 |
Arvinas Operations, Inc. |
Modulators of fak proteolysis and associated methods of use
|
|
EP3841100A1
(en)
|
2018-08-20 |
2021-06-30 |
Arvinas Operations, Inc. |
Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
|
|
KR102642203B1
(ko)
|
2018-09-07 |
2024-03-04 |
아비나스 오퍼레이션스, 인코포레이티드 |
급속 진행형 섬유육종 폴리펩티드의 표적화 분해를 위한 다중 고리 화합물 및 방법
|
|
JP7600123B2
(ja)
|
2018-10-15 |
2024-12-16 |
ニューリックス セラピューティクス，インコーポレイテッド |
ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物
|